ObjectiveIn order to evaluate the efficacy, safety and tolerability of adjunctive perampanel in children with refractory epilepsy. MethodsThis study collected medical records of 34 children with refractory epilepsy, who were admitted to Children’s Hospital of Soochow University from January 2020 to January 2021. By comparing the baseline status with the status at 4, 8, 12, 24, 36, and 48 weeks of follow-up, the efficacy and adverse reactions of perampanel were evaluated. ResultsThe mean age of the patients treated with perampanel was 8.1±4.1 years. The male-to-female ratio was 1: 1. After the addition of perampanel, the average responder rate at the 4th, 8th, 12th, 24th, 36th, 48th weeks were 37.5%, 46.7%, 50.0%, 47.4%, 53.8%, 42.9%. The adverse events were reported by 32.4%, and the retention rate was 88.2%. ConclusionsPerampanel has good efficacy, safety and tolerability in the treatment of refractory epilepsy. Moreover, personalized treatment and better baseline seizure control may increase the effectiveness and retention rate of perampanel.
ObjectiveTo observe the clinical efficacy and safety of Lacosamide (LCM) monotherapy in treating Benign epilepsy with centro-temporal spikes (BECT) at children. MethodsThe present research included 57 children with BECT who were treated with LCM monotherapy in the Children's Hospital Affiliated to Soochow University from June 2020 to June 2021. Among them, 26 were males and 31 were females, with an average age of (7.5±2.3) years. Analyze the efficacy and adverse reactions of 1, 2, 4, 6, 9 and 12 months after LCM treatment. The starting dose of LCM was 2 mg/(kg·d); increased 2 mg/(kg·d) every seven days; and titrated up to 4 ~ 8 mg/(kg·d) in children with weight ≥30 kg and <50 kg; titrated up to 6 ~ 12 mg/(kg·d) in children with weight ≥11 kg and <30 kg.ResultThe total effective rate was 94.12%; the cumulative control rate after 12-month medication was 86.27%; and the retention rate was 89.47%. Those all showed a higher rate. ConclusionLCM is significantly effective to BECT with less adverse reactions and more safety. It has high clinical application value.
Objective To investigate the associations of circulating inflammatory proteins and risk of psoriasis by using a two-sample Mendelian randomization (MR) approach. Methods Based on the genome-wide association study (GWAS) of inflammatory proteins and psoriasis, genetic variants associated with circulating inflammatory proteins were selected as instrumental variables (IVs), and genetic association data of psoriasis were extracted. The inverse-variance weighted method was used as the primary MR method, with statistical power analysis conducted to evaluate the test power. MR-Egger regression, weighted median, maximum likelihood, and MR Pleiotropy RESidual Sum and Outlier (PRESSO) tests were used to evaluate the influence of horizontal pleiotropy on the MR association estimates. Additionally, as sensitivity analysis, a GWAS of psoriasis from the FinnGen database was used as a replication dataset to evaluate the robustness of the results. Results A total of 558 single nucleotide polymorphisms associated with 74 inflammatory proteins were included. After False Discovery Rate (FDR) corrections, genetically predicted circulating levels of C-X-C motif chemokine ligand 9 (CXCL9) [odds ratio (OR)=1.76, 95% confidence interval (CI) (1.46, 2.11), P=2.31×10?9], C-C motif chemokine ligand 19 (CCL19) [OR=1.41, 95%CI (1.22, 1.62), P=2.97×10?6], and tumor necrosis factor-beta (TNFB) [OR=1.31, 95%CI (1.13, 1.52), P=3.56×10?4] were found to be significantly associated with an increased risk of psoriasis. Sensitivity analyses yielded similar results. Statistical power analysis indicated that the power to detect these associations was greater than 99%. Conclusion Genetically predicted circulating CXCL9, CCL19, and TNFB levels are positively associated with risk of psoriasis.
